All In Biotech

Drug Trial Radar · NCT01808768

Ocular Allergy Treatment Practical Impact Trial

To Assess the Impact of Ocular Allergy Treatment on Patients Using an Opthalmic Agent (or no Treatment) Versus Alcaftadine(Lastacaft™)

Last checked: Nov 20, 2026Latest source record: May 30, 2013 (this record)Source: ClinicalTrials.govMethods & limitations

Status unknown

Status

Status unknown

Enrollment

50

Planned (sponsor's estimate)

Start

Apr 2013

Primary completion

Oct 2013

Study completion Nov 2013

Sponsor

Lead sponsor
Starx Research Center, LLCIndustry
Sponsor type
Industry
First posted
Mar 11, 2013

More drug trials from this sponsor

Design

Study type
Interventional
Phase
Phase 4
Allocation
Not applicable (single group)
Model
Single group
Masking
None
Primary purpose
Treatment
Who can join
All sexes, from 18 years
Healthy volunteers
No

Summary

As written by the sponsor on the registry.

To study the impact of alcaftadine in patients treated with other opthalmic ocular agents (or specific topical opthalmic treatment) in an allergy subspecialist outpatient setting.

Conditions

  • Allergic Conjunctivitis
  • Rhinoconjunctivitis

Interventions

  • AlcaftadineDrug

    Alcaftadine 0.25% one dorp each eye daily for 1-2 weeks.

Primary outcomes

What the sponsor says the trial is designed to measure.

  1. Quality of Life- Eye Allergy Patient Impact QuestionnaireTime frame: 4 months

Locations

2 sites in 1 country. Site status is shown where the registry gives one.

  • STARx Research Center

    Edison, New Jersey · Recruiting

  • STARx

    Springfield, New Jersey · Recruiting

Contact details for sites and study staff are not shown here. To ask about taking part, use the contact information on the registry record.

For information only. Nothing on this page is investment, legal, tax or medical advice, and nothing here is an offer to sell or a solicitation of an offer to buy any security. The data comes from public government sources, which can be incomplete, delayed or wrong. Check the original record before relying on it.